Schizophrenia and bipolar disorder - Stanley Medical Research Institute Treatment Trials and Drug Development 2014 ($ 900,000)

The Stanley Medical Research Institute (SMRI) invites applications for its Treatment Trials and Drug Development programme. Deadline for applications is October 1, 2014. The program at SMRI is for the identification of medications that will improve the treatment of schizophrenia and bipolar disorder.

The programme consists of two parts:
• Regular Treatment Trials: The purpose of this program is to support the testing of medications to assess their efficacy for treating schizophrenia and bipolar disorder. SMRI is especially interested in supporting the testing of medications that are unlikely to be tested by pharmaceutical companies because they are not commercially profitable. At any given time, SMRI is supporting 40-50 treatment trials, the majority of which are on generic and/or off-label medications;
• Special Treatment Trials and Drug Development: SMRI also supports special treatment trials and occasional drug development. Special treatment trials are usually multi-center trials that require more than $ 300,000 per year to carry out. Such trials are usually reserved for medications for which preliminary SMRI-supported trials have been promising. SMRI has, in the past, also supported the development of promising medications at selected corporate biotechnology companies. At this time, such funds are fully committed, and new applications are not being accepted.

For most awards in the Regular Treatment Trials the maximum amount is $ 300,000 per year for up to three years, depending on the stage of development of compounds to be tested and the type of trial required. Special treatment trials may be funded at a higher level.